Psychedelics are moving back into the mainstream. According to a growing body of medical research, psychedelic drugs such as psilocybin and ketamine can have a profound impact on people struggling with mental health conditions, including depression, post-traumatic stress and substance-use disorders.
As a result, legal barriers are beginning to fall away. The U.S. Food and Drug Administration has designated psilocybin as a “breakthrough therapy,” for example, accelerating its path to approval, and recently released draft guidance for all clinical trials with psychedelic drugs.
Subscribe to Crosscut Talks on Apple Podcasts, Spotify, Stitcher, or Podbean.
For this episode of the Crosscut Talks podcast, we listen in on a conversation among science journalist and author Carl Zimmer, palliative and rehabilitative care physician Dr. Sunil Kumar Aggarwal and University of Washington psychiatry professor Dr. Nathan Sackett about the rapidly emerging field of psychedelics in psychotherapy.
They discuss these drugs’ specific effects on the brain, explain their use in clinical practice and in current research and explore some of the bigger questions raised — from the challenges of practicing medicine in a legal gray area to the nature of human consciousness.